Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

Journal of Immunology Research- Egypt

doi 10.1155/2016/8121985

Full Text

Abstract

Available in

Date

Authors

Publisher

Hindawi Limited

Related search

Antibody Response to Melanoma Helper-Peptide Vaccine Correlates With Survival

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

CTLA-4 Blockade Plus Adoptive T-Cell Transfer Promotes Optimal Melanoma Immunity in Mice

Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer ResearchAllergyImmunologyPharmacology
2015English

Us Burden of Illness Associated With Adjuvant Therapy for Stage I-Iii Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Considering Adjuvant Therapy for Stage II Melanoma

Cancer
Cancer ResearchOncology
2019English

Dual Blockade of PD-1 and CTLA-4 Combined With Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors—Response

Cancer Research
Cancer ResearchOncology
2014English

Radiotherapy Enhances Responses of Lung Cancer to CTLA-4 Blockade

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

CTLA-4 Blockade Synergizes With Cryoablation to Mediate Tumor Rejection

OncoImmunology
OncologyAllergyImmunology
2012English

Ipilimumab: An Anti-Ctla-4 Antibody for Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy